On this page
SATB2-associated syndrome
Also known as 2q33.1 microdeletion syndrome · Glass syndrome · SAS
SATB2-associated syndrome, sometimes called Glass syndrome, typically presents with significant developmental delay, particularly affecting speech, along with intellectual disability and distinctive facial characteristics. It is a rare condition that affects individuals from birth.
Available at Jeen Health
Clinical tests that include this
Overview
SATB2-associated syndrome (SAS), also known as Glass syndrome or 2q33.1 microdeletion syndrome, is a rare genetic condition that can impact an individual's development in various ways. It is characterised by a combination of developmental delay, intellectual disability, and challenges with speech development [PMID:27342930]. Many individuals with SAS also have distinctive facial features and may experience problems with their palate or teeth. The condition is considered rare, and its exact prevalence is not well established.
Symptoms & clinical features
Individuals with SATB2-associated syndrome often present with significant developmental delay, with speech and language development being particularly affected. Many children with SAS may have very limited or no verbal speech, and communication can be a major challenge [PMID:27342930]. Intellectual disability is common, varying in severity between individuals.
Beyond developmental milestones, a range of other features may be observed. These can include abnormalities of the palate, such as a high-arched palate or cleft palate, and dental anomalies like small teeth or crowded teeth. Some individuals may experience behavioural differences, such as hyperactivity or features that research suggests may be associated with autism spectrum disorder [PMID:27342930]. Skeletal features like osteoporosis or joint laxity have also been reported in some cases, contributing to the varied presentation of SAS.
Video: Genetics 101
Affected organs
SATB2-associated syndrome primarily affects the neurodevelopmental system, leading to its characteristic impacts on brain development, cognitive function, and speech. The central nervous system is therefore a key system involved. Additionally, the craniofacial structures are frequently affected, including the palate (roof of the mouth) and teeth. Bone density can also be a concern in some individuals, indicating a potential impact on the skeletal system. While SAS affects multiple systems, the primary concerns generally revolve around neurodevelopmental and craniofacial features.
Risks & severity
The severity of SATB2-associated syndrome can vary significantly among individuals, even within the same family, although most reported cases are de novo (not inherited). Most individuals experience significant developmental delay and intellectual disability, with speech impairment being particularly pronounced. While specific lifetime risks for other conditions are not fully established due to the rarity of SAS, the condition can lead to lifelong challenges requiring ongoing support. The age of onset for symptoms is typically from birth or early infancy, as developmental delays become apparent as a child grows.
Genetic causes
SATB2-associated syndrome is caused by pathogenic variants in the *SATB2* gene. This gene provides instructions for making a protein called 'special AT-rich sequence-binding protein 2'. The SATB2 protein is a transcription factor, meaning it helps to control the activity of many other genes [PMID:22057905]. It plays a crucial role in regulating processes involved in craniofacial development, such as the formation of the palate and teeth, and is also important for normal brain development.
When there is a pathogenic variant in *SATB2*, the protein may not be produced correctly, or it may not function as it should. This disruption to the SATB2 protein's role in gene regulation underlies the various developmental and physical features seen in SATB2-associated syndrome. The pathogenic variant can be a small change within the *SATB2* gene itself or a larger deletion of genetic material that includes the *SATB2* gene, often referred to as a 2q33.1 microdeletion.
- SATB2 SATB homeobox 2
Inheritance pattern
SATB2-associated syndrome follows an autosomal dominant inheritance pattern. This means that a person only needs one altered copy of the *SATB2* gene in each cell to develop the condition. Most cases of SAS are described as 'de novo', which means the genetic change occurs spontaneously in the affected individual and is not inherited from either parent. In such cases, the parents typically do not carry the pathogenic variant. If a person has SATB2-associated syndrome, there is a 50% chance in each pregnancy that their child could inherit the condition, although reproductive options can be discussed with a genetic counsellor.
Diagnosis & testing
Diagnosis of SATB2-associated syndrome is typically confirmed through genetic testing. If a healthcare professional suspects SAS based on a child's developmental profile, speech difficulties, and distinctive physical features, they may recommend specific genetic tests. These can include chromosomal microarray analysis to detect larger deletions that include the *SATB2* gene, or gene sequencing to identify smaller pathogenic variants within *SATB2*.
Genetic testing for suspected developmental disorders and intellectual disability falls under the NHS Genomic Medicine Service (GMS) pathways. Referrals for testing are usually made by a paediatrician, clinical geneticist, or other specialist involved in the child's care. Relevant NHS R-codes would be used for ordering specific tests (e.g., R14 for intellectual disability, R25 for developmental delay). Once a diagnosis is confirmed, individuals and their families are often referred to a clinical genetics service for further support and counselling.
Management & lifestyle
There is no specific cure for SATB2-associated syndrome, so management focuses on addressing the individual symptoms and providing supportive care to maximise an individual's potential. This typically involves a multidisciplinary team approach. Speech and language therapy is often a cornerstone of management, given the significant communication challenges. Occupational therapy and physiotherapy may also be beneficial for developmental delays and motor skills. Educational support tailored to individual needs is crucial.
Medical management may include addressing specific issues such as feeding difficulties, dental problems, or skeletal concerns, often involving specialists like orthodontists, gastroenterologists, or orthopaedists. Behavioural interventions may be helpful for some individuals. Regular follow-up with paediatricians and other specialists helps to monitor health and development and to adjust interventions as needed. Families are encouraged to engage with patient support groups and charities for additional resources and community support.
UK care pathway
In the UK, individuals suspected of having SATB2-associated syndrome typically enter the NHS Genomic Medicine Service (GMS) pathway. A referral, often from a paediatrician, will lead to an assessment by a clinical geneticist. These specialists can recommend appropriate genetic testing, guided by national testing directories and PanelApp R-codes (e.g., R14 for intellectual disability or R25 for developmental disorders). Following a diagnosis, families can access genetic counselling, which provides information about the condition, its inheritance, and support options. The GMS aims to ensure equitable access to genomic testing and expert advice across England.
Frequently asked questions
What is the typical outlook for someone with SATB2-associated syndrome?
The outlook for individuals with SATB2-associated syndrome varies, but most will experience lifelong developmental challenges, particularly with speech and cognitive abilities. With early and ongoing supportive therapies, individuals can make progress and improve their skills, contributing to their quality of life.
Is SATB2-associated syndrome always inherited from a parent?
No, most cases of SATB2-associated syndrome are 'de novo', meaning the genetic change occurs spontaneously in the affected individual and is not inherited from either parent. In a small number of cases, a parent might have a very mild form or be mosaic (have the change in only some cells) and pass it on.
Can therapies help with speech difficulties in SAS?
Yes, speech and language therapy is a very important part of managing SATB2-associated syndrome. While many individuals may have limited or no verbal speech, therapy can help develop alternative communication methods and support any emerging verbal skills, improving overall communication abilities.
What kind of support is available for families in the UK?
In the UK, families can access support through their local NHS services, including paediatricians, clinical genetics teams, and various therapists. There are also patient support groups and charities specific to SATB2-associated syndrome or broader rare conditions, offering community and resources.
Are there specific dietary recommendations for SATB2-associated syndrome?
There are no universal specific dietary recommendations for SATB2-associated syndrome, but some individuals may experience feeding difficulties or gastrointestinal issues. If these occur, a dietitian may be involved to help ensure adequate nutrition and manage any related symptoms.
References
- Adam MP, Bick S, Mirzaa GM. SATB2-Associated Syndrome. 1993. PMID: 29023086
- Zarate YA, Bosanko KA, Caffrey AR. Mutation update for the SATB2 gene. Human mutation. 2019. PMID: 31021519
- Bessa P, Newman AG, Yan K. Semaphorin heterodimerization in cis regulates membrane targeting and neocortical wiring. Nature communications. 2024. PMID: 39152101
- Zarate YA, Steinraths M, Matthews A. Bone health and SATB2-associated syndrome. Clinical genetics. 2018. PMID: 28787087
- Zarate YA, Bosanko KA, Caffrey AR. SATB2-associated syndrome in adolescents and adults. American journal of medical genetics. Part A. 2021. PMID: 33969926
- Zarate YA, Fish JL. SATB2-associated syndrome: Mechanisms, phenotype, and practical recommendations. American journal of medical genetics. Part A. 2017. PMID: 27774744
- Zarate YA, Kannan A, Bosanko KA. Growth in individuals with SATB2-associated syndrome. American journal of medical genetics. Part A. 2022. PMID: 35838081
- Thomason A, Pankey E, Nutt B. Speech, language, and feeding phenotypes of SATB2-associated syndrome. Clinical genetics. 2019. PMID: 31392730